Sothema Completes Acquisition of 99.99% of Soludia Maghreb’s Capital
The pharmaceutical group Sothema has announced the closing of the acquisition of 99.99% of the capital of Soludia Maghreb (“Soludia”), marking a significant strategic milestone in its development and strengthening its position in the hemodialysis sector in Morocco.
This operation was carried out through a dual structure. On one hand, Sothema acquired shares held by Mr. Abdellaziz Razkaoui, the fund Cap Mezzanine III (managed by CDG Invest Growth), and the Zine family. On the other hand, the operation included a capital increase of Sothema through a contribution in kind, executed by Mr. Abdellaziz Razkaoui and Cap Mezzanine III, involving the contribution of a portion of the shares they held in Soludia.
The increase in Sothema’s capital, including the contribution premium, amounted to a total of 630,428,614.60 dirhams. The prospectus related to this capital increase in kind received the approval of the Moroccan Capital Market Authority (AMMC) on December 9, 2025, confirming that the operation complies with current regulatory requirements.
A Strategic Strengthening in the Healthcare Sector
Through this acquisition, Sothema is consolidating its presence in the field of specialized medical solutions by integrating Soludia, a key player in the hemodialysis sector in Morocco.
Founded in 1996, Soludia offers a comprehensive range of products dedicated to hemodialysis, including powder bicarbonate cartridges, liquid solutions of acid and bicarbonate, as well as other pharmaceuticals distributed on behalf of international partners. The company also holds 40% of the capital of Hidropura Maroc, which specializes in the installation and maintenance of acid plants and water treatment rooms for hemodialysis centers.
Sothema: A Reference Pharmaceutical Player
Established in 1976, Sothema specializes in the production and marketing of medications, dietary supplements, and medical devices. The group is committed to making innovative treatments accessible in Morocco, sub-Saharan Africa, and the Middle East, covering the majority of therapeutic areas.
Its model relies both on licensed products developed in cooperation with 40 leading international laboratories in research and development and on generics and biosimilars marketed under its own brands.
CDG Invest Growth: A Structuring Financial Partner
On its side, CDG Invest Growth (CIG), an investment fund management company regulated by the AMMC and a subsidiary of CDG Invest, continues its equity investment strategy through this operation. CIG primarily targets medium and large Moroccan companies with strong growth potential, contributing to the development of the national economic fabric.
This operation confirms the ongoing consolidation dynamics in the Moroccan pharmaceutical sector and illustrates the increasing attractiveness of national players in the high-value segments of the healthcare system.
